• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA approves B&L plasma treatment of GP contact lenses

Article

Las Vegas-Bausch & Lomb has received U.S. FDA approval to add a cold oxygen plasma treatment to the manufacturing process of gas-permeable (GP) contact lenses made with Boston materials. B&L made the announcement recently at the American Optometric Association Congress and Annual American Optometric Student Association Conference.

Las Vegas-Bausch & Lomb has received U.S. FDA approval to add a cold oxygen plasma treatment to the manufacturing process of gas-permeable (GP) contact lenses made with Boston materials. B&L made the announcement recently at the American Optometric Association Congress and Annual American Optometric Student Association Conference.

"We have been studying plasma treatment for the past year, during which we have obtained valuable information about the treatment, and have developed an efficient, simple procedure for our materials. We believe this enhancement to the manufacturing process reinforces Boston's industry-leading position within the GP segment," said Jonathan Jacobson, Bausch & Lomb director-global GP business.

Plasma treatment is a process that bombards the lens surface with ions in a vacuum. This may reduce the lens hydration time by reducing the wetting angle and improve the comfort for the contact lens wearer without changing the finished lens properties.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
Edward Manche, MD
© 2024 MJH Life Sciences

All rights reserved.